Long-term clinical efficacy of grass-pollen immunotherapy

New England Journal of Medicine

Volumn 341, Issue 7, 1999, Pages 468-475

  Durham, Stephen R ^a,b   Walker, Samantha M ^a,b   Varga, Eva Maria ^a   Jacobson, Mikila R ^a   O'Brien, Fiona ^a   Noble, Wendy ^a   Till, Stephen J ^a   Hamid, Qutayba A ^c   Nouri Aria, Kayhan T ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIVASTINE; ALLERGEN; ALUTARD; ALUTARD SQ; CD3 ANTIGEN; CROMOGLYCATE DISODIUM; INTERLEUKIN 4; PREDNISOLONE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESENSITIZATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GRASS POLLEN; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SEASONAL VARIATION; SKIN BIOPSY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ALLERGENS; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERLEUKIN-4; MALE; MIDDLE AGED; POACEAE; POLLEN; PREDNISOLONE; REMISSION INDUCTION; RHINITIS, ALLERGIC, SEASONAL; RNA, MESSENGER; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0033549827     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908123410702     Document Type: Article

References (48)

1. von Mutius E, Fritzsch C, Weiland SK, Roll G, Magnussen H. Prevalence of asthma and allergic disorders among children in united Germany: a descriptive comparison. BMJ 1992;305:1395-9.
2. The International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994;49:Suppl:1-34.
3. Allergen immunotherapy: therapeutic vaccines for allergic diseases: Geneva: January 27-29, 1997. Allergy 1998;44:Suppl:1-42.
4. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265-9.
5. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405-13.
6. Dreborg S, Basomba A, Belin L, et al. Biological equilibration of allergen preparations: methodological aspects and reproducibility. Clin Allergy 1987;17:537-50.
7. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immu-notherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92: 644-51.
8. Distribution free methods. In: Armitage P, Berry G. Statistical methods in medical research. 3rd ed. Oxford, England: Blackwell Scientific, 1994: 448-68.
9. McKean JW, Ryan TA. An algorithm for obtaining confidence intervals and point estimates based on ranks in the two sample location problem. ACM Trans Math Software 1977;3:183-5.
10. Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet 1954;1:1055-7.
11. McAllen MK. Hyposensitisation in grass pollen hay fever a double blind trial of alumn precipitated pollen extract and depot emulsion pollen extract compared with placebo injections. Acta Allergol 1969;24:421-31.
12. Ortolani C, Pastorello E, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73: 283-90.
13. Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, place-bo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol 1987;80:591-8.
14. Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol 1989;84:546-56.
15. Pastorello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992;47:281-90.
16. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;51:489-500.
17. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996;334:501-6.
18. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma. A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151:969-74.
19. Adkinson NF Jr, Eggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31.
20. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523-9.
21. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52: 914-20.
22. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: in vivo aspects. Clin Allergy 1984; 14:209-19.
23. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;73:484-9.
24. Norman PS, Creticos PS, Marsh DG. Frequency of booster injections of allergoids. J Allergy Clin Immunol 1990;85:88-94.
25. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3.
26. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100:293-300.
27. Imada M, Simons FE, Jay FT, Hayglass KT. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995; 85:373-80.
28. Till S, Durham S, Dickason R, et al. IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression. Immunology 1997;91:53-7.
29. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991;12: 392-5.
30. Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988;140:4193-8.
31. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci U S A 1993;90:3730-4.
32. Lopez AF, Sanderson CJ, Gamble JR, Campbell HD, Young IG, Vadas MA. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 1988;167:219-24.
33. Holgate ST. The mast cell and its function in allergic disease. Clin Exp Allergy 1991;21:Suppl 3:11-6.
34. Lichtenstcin LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever: relationship to clinical severity and the results of immunotherapy. J Clin Invest 1973;52:472-82.
35. Gleich GJ, Zimmermann EM, Henderson LL, Yunginger JW. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol 1982;70:261-71.
36. Otsuka H, Mezawa A, Ohnishi M, Okubo K, Seki H, Okuda M. Changes in nasal metachromatic cells during allergen immunotherapy. Clin Exp Allergy 1991;21:115-9.
37. Creticos PS, Adkinson NF Jr, Kagey-Sobotka A, et al. Nasal challenge with ragweed pollen in hay fever patients: effect of immunotherapy. J Clin Invest 1985;76:2247-53. [Erratum, J Clin Invest 1986;78:1421.]
38. Furin MJ, Norman PS, Creticos PS, et al. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity. J Allergy Clin Immunol 1991;88:27-32.
39. Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82:470-80.
40. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97: 1356-65.
41. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254-60.
42. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178:2123-30.
43. Ebner C, Siemann U, Bohle B, et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for PhI p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27: 1007-15.
44. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157-64.
45. MacGlashan D Jr, White JM, Huang SK, Ono SJ, Schroeder JT, Liehtenstein LM. Secretion of IL-4 from human basophils: the relationship between IL-4 mRNA and protein in resting and stimulated basophils. J Immunol 1994;152:3006-16.
46. Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992;176:1381-6.
47. Moqbel R, Ying S, Barkans J, et al. Identification of mRNA for interleukin-4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939-47.
48. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures IP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitiza-tions in children. I Allergy Clin Immunol 1997;99:450-3.